一種針對肺、卵巢、乳房癌癥進行早期檢測和危險分層的新方法，將由創建新型蛋白質組學技術來完稱，其原理是精確地檢測和測定特異性的蛋白質片斷，這些片斷是人血液中可能的疾病生物學指標。

PerkinElmer公司(Boston, MA, USA)已經宣布了一項為期5年與George Mason大學(Manassas, VA, USA)合作的科研計劃，以實現這種新型檢測方法。PerkinElmer公司提供基因生物指標領域新技術和科學方法。來自這兩個機構的科學家將共同合作設計新型臨床檢測平臺，該平臺將同時對特異性蛋白質片斷的進行氨基酸鑒別和特定分子量進行鑒別，以發現生物指標。
 
Proteomics Technology May Detect Early Cancer
 
A new approach for early lung, ovarian, and breast cancer detection and risk stratification is being developed by creating a new proteomics technology to accurately detect and measure specific protein fragments in human blood that are potential biomarkers for disease.

PerkinElmer, Inc. (Boston, MA, USA), has announced a five-year research-collaboration agreement with George Mason University (Manassas, VA, USA) to work on this new approach. PerkinElmer is providing new technology and scientific expertise in genetic biomarker expression. Scientists from both organizations will work together to design new types of clinical assay latforms that use both the amino acid identification of a specific protein fragment and its specific mass to identify the biomarker.